-
Calpain, BDNF/TrkB, and Offspring Cognition
2026-09-15
A 2025 Neuropharmacology study links maternal non-obstetric surgery during pregnancy to excessive calpain activity, hippocampal BDNF/TrkB disruption, and cognitive deficits in offspring. Pharmacological calpain inhibition with MDL 28170 partially restored synaptic markers, neuronal structure, and behavioral performance, supporting calpain as a mechanistic target while leaving important questions about selectivity and translation.
-
CCCP for Mitochondrial Morphology Assays
2026-09-15
CCCP provides a controlled way to perturb mitochondrial membrane potential while imaging morphology in living cells. Its strongest use is as a timed calibration stressor for microscopy and AI workflows, not as a standalone disease biomarker or clinical reagent.
-
BOP Reagent Workflow for Prodrug-Oriented Synthesis
2026-09-14
This practical guide shows how BOP reagent can support carboxyl group activation, phenyl ester preparation, and amide bond formation in peptide and prodrug workflows. It also translates a carrier-free OSCC prodrug study into actionable synthesis, analytical, and troubleshooting decisions without overstating the paper’s evidence.
-
PP 2 (AG 1879) Workflows for Src Signaling
2026-09-14
PP 2 (AG 1879) helps researchers separate Src-family kinase activity from ROS, calcium-channel, and vehicle effects in cancer, immune, and vascular assays. This guide translates the compound’s selectivity profile and a recent arterial-contraction study into practical workflows, controls, and troubleshooting decisions.
-
Cyclic di-GMP Controls Biofilm Persistence
2026-09-13
The 2024 eLife study identifies cyclic di-GMP as a small-molecule antitoxin that restrains the genotoxic toxin HipH during early biofilm development. Its findings connect cell adhesion, genome instability, and antibiotic persistence, providing a mechanistic framework for studying biofilm formation regulation beyond simple diffusion or nutrient-limitation models.
-
TBST Workflows for Cleaner Immunoassays
2026-09-12
TBST combines buffered saline with Tween 20 to make antibody blocking, incubation, and washing more reproducible across Western blotting, immunofluorescence, and immunohistochemistry. This guide connects practical buffer control with a cancer-cell invasion study, showing how cleaner antibody data can strengthen mechanistic conclusions without overstating what the assay proves.
-
BI 2536: A Practical PLK1 Inhibitor Workflow
2026-09-12
BI 2536 combines nanomolar PLK1 potency with a workflow that connects mitotic arrest, apoptosis, and checkpoint-complex biochemistry. This guide shows how to move from dose–response experiments to mechanistic p31comet assays and tumor xenograft model planning while avoiding common interpretation and solubility errors.
-
HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus
2026-09-11
The HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus supports in vitro transcription of randomly Cy3-modified RNA probes for applications such as in situ hybridization, Northern blotting, and fluorescence-based RNA analysis. It is intended for research use only and should not be used for diagnostic, therapeutic, clinical, or medical workflows.
-
Triacetin Workflows for Translational Research
2026-09-11
Triacetin supports distinct workflows in glioblastoma apoptosis studies, metabolic signaling, and ocular formulation screening. This guide shows how to separate its formulation role from its bioactivity, select defensible concentrations, and build controls that improve assay interpretation.
-
2',7'-Dichlorofluorescein diacetate ROS Workflow
2026-09-10
Build a practical intracellular ROS measurement workflow around 2',7'-Dichlorofluorescein diacetate for microscopy, flow cytometry, and plate-based assays. The approach connects redox readouts with a pH/ROS-responsive pancreatic cancer nanocarrier study while emphasizing controls, normalization, and the probe’s limits as a general rather than selective oxidative-stress indicator.
-
Ferrostatin-1 in Ferroptosis Assay Workflows
2026-09-10
Ferrostatin-1 (Fer-1) provides a practical pharmacological rescue control for distinguishing ferroptosis from nonspecific cytotoxicity. This guide translates a rheumatoid arthritis fibroblast-like synoviocyte study into reproducible workflows for lipid ROS, viability, inflammatory signaling, and pathway-validation experiments.
-
SmD2 Acetylation, Splicing, and PARP Inhibitor Sensitivity
2026-09-09
This study identifies SmD2 as a mechanistic link between spliceosome regulation, BRCA1/FANC cassette-exon processing, and PARP inhibitor sensitivity in hepatocellular carcinoma. Its findings support an acetylation-centered strategy in which HDAC2 inhibition and PARP blockade may improve responses in preclinical HCC models.
-
Betaine Hydrochloride for Enzyme Assays
2026-09-09
Betaine hydrochloride supports controlled, water-based screening in metabolic enzyme research, protease assays, cell culture, and molecular biology workflows. This guide separates evidence from the oridonin cancer literature and shows how to use the compound as a defined matrix variable rather than assuming it is an anticancer treatment.
-
Gemcitabine Workflows for DNA Damage Research
2026-09-08
Build reproducible Gemcitabine experiments around replication stress, checkpoint activation, and apoptosis rather than relying on a single viability endpoint. This guide also extends the workflow into cholangiocarcinoma metabolism and macrophage co-culture models while clearly separating established evidence from exploratory assay design.
-
AT13387: Hsp90 Inhibitor Workflows for Cancer Research
2026-09-08
AT13387 combines high-affinity Hsp90 engagement with a practical workflow for studying client-protein loss, cell cycle arrest, and apoptosis induction. This guide also shows how to separate Hsp90-driven cancer phenotypes from membrane-rupture and secretion signals highlighted by recent norovirus research.